CNSX:STIL

Stock Analysis Report

Executive Summary

StillCanna Inc., an early stage life sciences company, focuses on the cultivation and extraction of cannabidiol in Europe.


Snowflake Analysis

Excellent balance sheet and overvalued.

Share Price & News

How has StillCanna's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: STIL's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-14.3%

STIL

13.3%

CA Pharmaceuticals

4.5%

CA Market


1 Year Return

-95.9%

STIL

-74.3%

CA Pharmaceuticals

-24.5%

CA Market

Return vs Industry: STIL underperformed the Canadian Pharmaceuticals industry which returned -73.5% over the past year.

Return vs Market: STIL underperformed the Canadian Market which returned -26% over the past year.


Shareholder returns

STILIndustryMarket
7 Day-14.3%13.3%4.5%
30 Day-45.5%-18.9%-20.1%
90 Day-75.5%-35.3%-24.9%
1 Year-95.9%-95.9%-74.3%-74.3%-22.0%-24.5%
3 Year20.0%20.0%-15.3%-15.9%-14.2%-22.2%
5 Yearn/a199.2%199.2%-1.9%-16.5%

Price Volatility Vs. Market

How volatile is StillCanna's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is StillCanna undervalued compared to its fair value and its price relative to the market?

0.16x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate STIL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate STIL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: STIL is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: STIL is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate STIL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: STIL is good value based on its PB Ratio (0.2x) compared to the CA Pharmaceuticals industry average (0.9x).


Next Steps

Future Growth

How is StillCanna forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

66.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as StillCanna has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has StillCanna performed over the past 5 years?

-91.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: STIL is currently unprofitable.

Growing Profit Margin: STIL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: STIL is unprofitable, and losses have increased over the past 5 years at a rate of -91.6% per year.

Accelerating Growth: Unable to compare STIL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: STIL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-9.9%).


Return on Equity

High ROE: STIL has a negative Return on Equity (-52.28%), as it is currently unprofitable.


Next Steps

Financial Health

How is StillCanna's financial position?


Financial Position Analysis

Short Term Liabilities: STIL's short term assets (CA$12.8M) exceed its short term liabilities (CA$1.2M).

Long Term Liabilities: STIL's short term assets (CA$12.8M) exceed its long term liabilities (CA$261.5K).


Debt to Equity History and Analysis

Debt Level: STIL is debt free.

Reducing Debt: STIL had no debt 5 years ago.


Balance Sheet

Inventory Level: STIL has a low level of unsold assets or inventory.

Debt Coverage by Assets: STIL's debt is not covered by short term assets (assets are -4.6162559110413E+17x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: STIL has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: STIL has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of -76.9% each year.


Next Steps

Dividend

What is StillCanna's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate STIL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate STIL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if STIL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if STIL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of STIL's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Jason Dussault

1.83s

Tenure

CA$14,000

Compensation

Mr. Jason Dussault has been the Chief Executive Officer of StillCanna Inc. since April 20, 2018 and Director since May 22, 2018 and serves as its President. Mr. Dussault was the Founder and served as the C ...


CEO Compensation Analysis

Compensation vs Market: Jason's total compensation ($USD0.00) is below average for companies of similar size in the Canadian market ($USD159.52K).

Compensation vs Earnings: Insufficient data to compare Jason's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Jason Dussault
CEO, President & Director1.83yrsCA$14.00k0.099% CA$6.6k
Joel Leonard
Chief Financial Officer1.83yrsCA$15.00k0.24% CA$15.8k
Richard Haslinger
Consultant4.42yrsno datano data
Jason Leikam
Consultant4.42yrsno datano data
Adam Kim
Promoterno datano datano data
Marc Crimeni
no datano data4.27% CA$284.2k
Shae De Jaray
COO, Senior Engineer & Director0.67yrno data2.57% CA$170.9k
Paul van Issum
President of European Operationsno datano datano data

1.8yrs

Average Tenure

47yo

Average Age

Experienced Management: STIL's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Jason Dussault
CEO, President & Director1.83yrsCA$14.00k0.099% CA$6.6k
Shae De Jaray
COO, Senior Engineer & Director0.67yrno data2.57% CA$170.9k
Warren Robinson
Independent Director0.83yrno datano data
William MacDonald
Independent Director0.67yrno datano data
Krystyna Skalicka-Wozniak
Member of Advisory Board1.17yrsno datano data
Krzysztof Wojtanowski
Member of Advisory Board1.17yrsno datano data
Lidia Grabowska
Member of Advisory Board1.17yrsno datano data
Thomas Svensson
Member of Advisory Board1.17yrsno datano data
Bogdan Wenta
Member of Advisory Board1.17yrsno datano data

1.2yrs

Average Tenure

Experienced Board: STIL's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 249%.


Top Shareholders

Company Information

StillCanna Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: StillCanna Inc.
  • Ticker: STIL
  • Exchange: CNSX
  • Founded:
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$6.652m
  • Shares outstanding: 110.87m
  • Website: https://www.stillcanna.com

Location

  • StillCanna Inc.
  • 905 West Pender Street
  • Suite 503
  • Vancouver
  • British Columbia
  • V6C 1L6
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
STILCNSX (Canadian National Stock Exchange)YesCommon SharesCACADMay 2012
484DB (Deutsche Boerse AG)YesCommon SharesDEEURMay 2012
SCNN.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDMay 2012

Biography

StillCanna Inc., an early stage life sciences company, focuses on the cultivation and extraction of cannabidiol in Europe. The company was formerly known as EVI Global Group Developments Corp. and changed its name to StillCanna Inc. in March 2019. The company is headquartered in Vancouver, Canada. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/31 03:12
End of Day Share Price2020/03/30 00:00
Earnings2019/10/31
Annual Earnings2019/07/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.